2,000,000 Shares in Myomo, Inc. (NYSEAMERICAN:MYO) Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC bought a new position in Myomo, Inc. (NYSEAMERICAN:MYO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,000,000 shares of the company’s stock, valued at approximately $1,200,000. AIGH Capital Management LLC owned approximately 9.56% of Myomo at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Virtu Financial LLC raised its position in Myomo by 516.0% during the first quarter. Virtu Financial LLC now owns 108,957 shares of the company’s stock valued at $82,000 after purchasing an additional 91,269 shares during the period. Two Sigma Investments LP purchased a new stake in Myomo during the fourth quarter valued at approximately $36,000. Renaissance Technologies LLC purchased a new stake in Myomo during the second quarter valued at approximately $41,000. Worth Venture Partners LLC raised its position in Myomo by 11.0% during the first quarter. Worth Venture Partners LLC now owns 153,936 shares of the company’s stock valued at $586,000 after purchasing an additional 15,250 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Myomo by 25.4% during the first quarter. Dimensional Fund Advisors LP now owns 22,730 shares of the company’s stock valued at $87,000 after purchasing an additional 4,609 shares during the period. 21.41% of the stock is currently owned by hedge funds and other institutional investors.

Myomo Stock Performance

Shares of MYO traded up $0.14 during mid-day trading on Friday, reaching $1.06. 1,533,159 shares of the company’s stock traded hands, compared to its average volume of 461,188. The stock has a market cap of $22.37 million, a price-to-earnings ratio of -1.26 and a beta of 0.90. Myomo, Inc. has a 12 month low of $0.37 and a 12 month high of $1.81.

Myomo (NYSEAMERICAN:MYO) last released its earnings results on Wednesday, August 9th. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). Myomo had a negative return on equity of 106.09% and a negative net margin of 49.70%. The firm had revenue of $5.96 million for the quarter, compared to analysts’ expectations of $5.75 million. As a group, analysts predict that Myomo, Inc. will post -0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Maxim Group began coverage on Myomo in a research note on Thursday, May 25th. They set a “buy” rating on the stock.

Insider Buying and Selling

In other news, CEO Paul R. Gudonis acquired 48,400 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were bought at an average price of $0.74 per share, with a total value of $35,816.00. Following the completion of the purchase, the chief executive officer now directly owns 878,245 shares in the company, valued at $649,901.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Paul R. Gudonis bought 42,500 shares of the stock in a transaction on Monday, August 28th. The stock was bought at an average price of $0.75 per share, for a total transaction of $31,875.00. Following the completion of the acquisition, the chief executive officer now directly owns 792,845 shares in the company, valued at $594,633.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paul R. Gudonis bought 48,400 shares of the stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $0.74 per share, with a total value of $35,816.00. Following the acquisition, the chief executive officer now owns 878,245 shares of the company’s stock, valued at $649,901.30. The disclosure for this purchase can be found here. Insiders have bought a total of 140,899 shares of company stock valued at $97,690 over the last quarter. 3.20% of the stock is owned by corporate insiders.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.